News - Acorda Therapeutics

Filter

Current filters:

Acorda Therapeutics

Popular Filters

Actavis files for generic version of Acorda’s Ampyra

Actavis files for generic version of Acorda’s Ampyra

27-06-2014

US biotech firm Acorda Therapeutics has been advised that Ireland-headquartered generics major Actavis…

Acorda TherapeuticsActavisAmpyraGenericsHealth Medical PharmaMedicinePharmaceutical sciencesPharmacologyRegulationUS Food and Drug AdministrationUSA

FDA issues CRL over Acorda's Plumiaz marketing application

FDA issues CRL over Acorda's Plumiaz marketing application

02-05-2014

There was disappointment for US biotech firm Acorda Therapeutics, which says it has received a complete…

Acorda TherapeuticsBiotechnologyNeurologicalPlumiazRegulationUSA

Acorda Therapeutics appoints former BG Medicine vice president as chief financial officer

Acorda Therapeutics appoints former BG Medicine vice president as chief financial officer

09-10-2013

Acorda Therapeutics has announced that Michael Rogers has joined the company as chief financial officer.

Acorda TherapeuticsBiotechnologyBoardroomNorth America

Acorda's dalfampridine promising in mid-stage trial for post-stroke deficits

16-04-2013

USA-based Acorda Therapeutics (Nasdaq: ACOR) has reported that a proof-of-concept trial (Phase II) found…

Acorda TherapeuticsdalfampridineNeurologicalPharmaceuticalResearch

Low-dose Ampyra fails in multiple sclerosis study, says Acorda

15-08-2012

USA-based biotech firm Acorda Therapeutics (Nasdaq: ACOR) has announced top line results from a post-marketing…

Acorda TherapeuticsAmpyraBiotechnologyMetabolicsNeurologicalPharmaceuticalResearch

US FDA points to seizure risk with Acorda's MS drug Ampyra

25-07-2012

The US Food and Drug Administration has issued a warning about the risk of seizures in patients with…

Acorda TherapeuticsAmpyraNeurologicalNorth AmericaPharmaceuticalRegulation

Back to top